Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 7Recruiting 5Unknown 1Terminated 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Classical hematology 1

Conditions

Lymphoma 370Lymphoma, Non-Hodgkin 348Leukemia, Lymphocytic, Chronic, B-Cell 322Precursor Cell Lymphoblastic Leukemia-Lymphoma 291Lymphoma, Large B-Cell, Diffuse 244Lymphoma, Follicular 236Leukemia 198Hodgkin Disease 171Lymphoma, Mantle-Cell 164Leukemia, Myeloid, Acute 160Multiple Myeloma 134Myelodysplastic Syndromes 130Recurrence 125Burkitt Lymphoma 123Lymphoma, B-Cell, Marginal Zone 120Lymphoma, T-Cell, Cutaneous 92Neoplasms 82Mycosis Fungoides 82Lymphoma, B-Cell 82Waldenstrom Macroglobulinemia 74Leukemia, Myelogenous, Chronic, BCR-ABL Positive 70Sezary Syndrome 67Lymphoma, Large-Cell, Immunoblastic 65Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 57Lymphoma, Large-Cell, Anaplastic 54Neoplasms, Plasma Cell 52Myeloproliferative Disorders 52Primary Myelofibrosis 46Hematologic Neoplasms 44Blast Crisis 43

Interventions

epratuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Hemostatic Disorders × Lymphoid × Clear all
NCT00113802 2021-08-19

Study of Epratuzumab (hLL2) in Patients With Waldenstrom's Macroglobulinemia

Gilead Sciences

Phase 2 Terminated
31 enrolled
Lymphoid

Hematologic Diseases, Lymphoproliferative Disorders, Waldenstrom Macroglobulinemia, Paraproteinemias, Hemostatic Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡